logo

Biogen Inc. (BIIB)



Trade BIIB now with
  Date
  Headline
12/13/2019 7:40:26 AM Biogen: Primary Endpoint Of Phase 2 PASSPORT Study Was Not Met
12/3/2019 8:40:57 AM Biogen Announces Positive Phase 2 Study Results For Cutaneous Lupus Erythematosus And Systemic Lupus Erythematosus
11/22/2019 7:33:39 AM Biogen Announces Detailed Results From Phase 3 EVOLVE-MS-2 Study
11/12/2019 7:02:09 AM Alkermes Receives $150 Mln Milestone Payment From Biogen Triggered By Recent FDA Approval Of VUMERITY
11/6/2019 7:43:50 AM Biogen Enter New Deal With Samsung Bioepis To Expand Biosimilars Portfolio
10/30/2019 7:31:19 AM Biogen And Alkermes Announce FDA Approval Of VUMERITY For Multiple Sclerosis
10/22/2019 7:06:20 AM Biogen Q3 EPS $8.39; Non-GAAP EPS $9.17
10/22/2019 6:37:26 AM Biogen Plans To Submit BLA For Aducanumab In Early 2020
10/22/2019 6:36:02 AM Biogen Plans To Pursue Regulatory Approval For Aducanumab
10/3/2019 8:01:34 AM Biogen Canada Announce Positive Results From The NURTURE Study
10/1/2019 8:14:12 AM Biogen: Michael Ehlers, EVP, Research And Development, To Leave
9/13/2019 8:02:31 AM Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
  
 
>